Breast Cancer Trial Setback
AstraZeneca breast cancer pill misses key goal in late-stage trial, sending shares lower.
Anonymous
Key Points
1
Camizestrant works by blocking and destroying the estrogen receptor, preventing estrogen from fueling hormone-receptor-positive breast cancer cells.
2
In the successful SERENA-6 trial, camizestrant extended median progression-free survival to 16.8 months, compared with 9.2 months for standard care, in patients whose tumors acquired an ESR1 mutation during first-line treatment.
3
RBC Capital analyst Trung Huynh called the SERENA-4 result a “manageable disappointment,” saying it removed short-term uncertainty without changing the long-term investment outlook for camizestrant.
4
Barclays analyst James Gordon said the result was anticipated by some investors after a similar Roche drug combination failed in March; Jefferies estimated camizestrant could eventually generate more than $5 billion in peak annual sales.
5
The failed SERENA-4 study involved patients whose breast cancer had returned or spread but who had not yet received treatment for their advanced disease, according to AstraZeneca.
AstraZeneca's breast cancer pill camizestrant failed to meet its main goal in a late-stage trial, missing a key milestone for the drug's expansion. The medication, marketed as Etcamah, did not significantly improve progression-free survival when combined with Pfizer's Ibrance in 1,371 previously untreated patients with advanced hormone-receptor-positive, HER2-negative breast cancer, according to STAT News. The setback sent AstraZeneca shares lower in after-hours trading.
The failed SERENA-4 trial contrasts sharply with the drug's recent success in a narrower patient group. In the SERENA-6 trial, camizestrant reduced the risk of progression or death by 56% in patients whose tumors developed an ESR1 mutation after initial treatment, extending median progression-free survival to 16.8 months versus 9.2 months with standard care, STAT News reported.
How Camizestrant Attacks Breast Cancer Cells
Camizestrant works by blocking and destroying the estrogen receptor, a protein that fuels hormone-receptor-positive breast cancer growth. By preventing estrogen from activating cancer cells, the drug aims to slow or stop tumor progression. This mechanism has proven effective in patients whose cancers develop ESR1 mutations, which make tumors resistant to standard hormone therapies, according to Fierce Pharma.
Why The Broader Trial Failed To Deliver
The SERENA-4 trial tested camizestrant in a much larger group: patients with advanced breast cancer who had not yet received any treatment for their metastatic disease. Unlike the ESR1-positive patients in SERENA-6, this broader population did not show meaningful survival improvements when the pill was added to Ibrance and hormone-suppressing therapy, STAT News reported.
Some analysts anticipated this outcome. Barclays analyst James Gordon noted that a similar drug combination from Roche failed in March, signaling potential weakness for this approach across the industry. The result was called a "manageable disappointment" by RBC Capital analyst Trung Huynh, who said it removes short-term uncertainty without derailing the drug's longer-term prospects.
Long-Term Sales Potential Remains Intact
Wall Street remains bullish on camizestrant's future despite the SERENA-4 setback. Jefferies estimated the drug could eventually generate more than $5 billion in peak annual sales, primarily in patients with ESR1-mutant tumors where efficacy has already been proven. Full trial data is still expected at an upcoming medical conference, which could provide additional context for the disappointing results.
A Setback For Oral SERD Class Therapies
The failure adds to a poor track record for oral SERDs—drugs that selectively degrade the estrogen receptor—in first-line breast cancer treatment. Fierce Pharma reported that multiple oral SERDs have struggled in broader patient populations, suggesting the drugs work best when targeted to specific genetic subtypes like ESR1 mutations rather than deployed as universal frontline therapies.
Sentiment
Mostly NegativeNEGATIVENEUTRALPOSITIVE
Publishers
13
Articles
39
Reach
52
A
AnonymousAuthor
